The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.
Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.
The HSD3B1 CC pathogenic variant does not add prognostic information to standard clinical variables for men receiving abiraterone or enzalutamide for metastatic castration-resistant prostate cancer, study findings indicate.
A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.
Adding an androgen receptor inhibitor to androgen deprivation therapy significantly improves the overall survival of men with nonmetastatic castration-resistant prostate cancer, according to results from three trials.
Positron-emission tomography using the novel prostate-specific membrane antigen targeted 18F-DCFPyL tracer shows “excellent diagnostic performance” in men with biochemically recurrent prostate cancer, researchers report.
Men with advanced prostate cancer who receive the gonadotropin-releasing hormone antagonist relugolix are more likely to have sustained suppression of testosterone than those treated with leuprolide acetate, HERO trial data show.
Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.
Men with metastatic castration-resistant prostate cancer (mCRPC) who carry the CC genotype of the HSD3B1 c.1245A>C variant have worse responses to first-line abiraterone and enzalutamide than those with an AA or AC genotype, research shows.
The phase 3 IMbassador250 trial has failed to show any significant improvement in metastatic castration-resistant prostate cancer outcomes with the addition of atezolizumab to enzalutamide.
Stereotactic ablative radiotherapy is associated with a significantly lower risk for disease progression at 6 months relative to observation in men with oligometastatic prostate cancer, phase 2 study data show.
Prospective data now confirm that White men with low-volume metastatic castration-sensitive prostate cancer who have the adrenal-permissive HSD3B1 genotype have poorer outcomes than those with the adrenal-restrictive genotype.
US researchers have developed predictive models that could help identify men with prostate cancer who are likely to undergo pathologic downgrading after radical prostatectomy and therefore may be suitable candidates for active surveillance.
A combined approach using both MRI-targeted and systematic biopsy provides improved diagnostic accuracy for the detection of prostate cancer versus either strategy alone, say the Trio researchers.
The addition of pembrolizumab to enzalutamide has “modest activity” against metastatic castration-resistant prostate cancer that has become resistant to enzalutamide, say the KEYNOTE-199 researchers.